FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
Aathira Sujathan Nair,Ashutosh Kumar Singh,Astik Kumar,Sunil Kumar,Sunitha Sukumaran,Vishal Payyalot Koyiparambath,Leena K. Pappachen,T. M. Rangarajan,Hoon Kim,Bijo Mathew
DOI: https://doi.org/10.3390/pr10102054
IF: 3.5
2022-10-12
Processes
Abstract:As people around the world regard 2020 as the year of COVID-19, the medical community considers this year to be the second-best year, shared with the year 1996, with respect to the number of drug molecules approved by the US Food and Drug Administration (FDA). Both years, 2020 and 1996, had a record of 53 new drug molecules approved by the FDA. In the year 2020, 53 new chemical entities and 13 biological medicines were approved, including 10 monoclonal antibodies, 2 antibody-drug conjugates, 3 peptides, and 2 oligonucleotides. Among them, most of the compounds were found to have fluorine or fluorine-containing functional groups exhibiting numerous pharmacological activities. Herein, we summarized the trifluoromethyl (TFM, -CF3)-group-containing FDA-approved drugs for the last 20 years. This article specially features and details the previous 20-year literature data, covering CF3-incorporated potential drug molecules, including their syntheses and uses for various diseases and disorders. The review covers the detailed chemistry of 19 FDA-approved drugs in the past 20 years, which contains the TFM group as one of the pharmacophores.
engineering, chemical